Acrigen Biosciences

company

About

Acrigen Biosciences is dedicated to making gene editing safe.

  • 1 - 10

Details

Last Funding Type
Grant
Last Funding Money Raised
$1M
Industries
Biotechnology,Genetics,Life Science
Founded date
Jan 1, 2019
Number Of Employee
1 - 10
Operating Status
Active

Acrigen Biosciences is dedicated to making gene editing safe. It develops technologies to improve efficiency and enhance the safety of CRISPR-Cas based gene editing. CRISPR-Cas system which enables the precise enzymatic editing of genes is one of the most exciting and promising techniques to be developed in the last few years with the capability to prevent or cure many devastating diseases.

It was founded in 2019 and is headquartered in Berkeley, California.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$1.22M
Acrigen Biosciences has raised a total of $1.22M in funding over 2 rounds. Their latest funding was raised on Feb 24, 2022 from a Grant round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Feb 24, 2022 Grant $1M 1 National Science Foundation Detail
Sep 9, 2020 Grant $225K 1 National Science Foundation Detail

Investors

Number of Lead Investors
Number of Investors
2
1
Acrigen Biosciences is funded by 1 investors. National Science Foundation are the most recent investors.
Investor Name Lead Investor Funding Round
National Science Foundation Yes Grant